ArticleDiscover oncology2025
Global trends and future directions in COVID-19 and leukemia research from 2020 to 2024.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 has disproportionately affected leukemia patients, with outcomes significantly worse than those in the general population due to their immunocompromised status. Despite substantial growth in COVID-19 and leukemia research, there remains a lack of bibliometric analyses examining the global research landscape in this critical domain.
methodsThis study employed bibliometric methodology to analyze 346 publications examining the intersection of COVID-19 and leukemia from 2020 to 2024 using the Web of Science Core Collection database. Data visualization and analysis were conducted using VOSviewer (version 1.6.19), CiteSpace (version 6.2.R3), and the biblioshiny R package.
resultsThe analysis encompassed 66 countries, with publications from multiple institutions and researchers across 173 journals. The United States leads with 96 publications and 2,778 citations, with Tel Aviv University as the most influential institution. The Cureus Journal Of Medical Science has published the most papers (counts = 21), while the Blood has the most co-citations (1,177). Tamar Tadmor is the most prolific author (counts = 11, citations = 916), and Y. Herishanu has the highest co-citations (n = 104). Current research hotspots primarily encompass COVID-19 clinical outcomes, vaccine immunogenicity patterns, disease-specific management strategies, and therapeutic treatment adaptations. Future research directions should focus on long-term outcome monitoring, precision vaccination strategies, digital healthcare integration, global collaborative frameworks, and crisis preparedness mechanisms.
conclusionThis bibliometric analysis indicates that COVID-19 has transformed leukemia research, moving from broad immunocompromised patient strategies to precision medicine integrating infection risk. The established knowledge base and international collaboration provide a solid foundation for future infectious disease challenges in vulnerable cancer populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.